Reuters logo
BRIEF-NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm
May 1, 2017 / 11:52 PM / 7 months ago

BRIEF-NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm

May 2 (Reuters) - Yungjin Pharm Co Ltd:

* announced it has entered into global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders

* will now initiate activities in preparation for next clinical study in Europe and/or in U.S.

* NeuroVive will pay Yungjin Pharm upfront payments of $1 million at signing

* NeuroVive will pay Yungjin Pharm additional $1 million after completion of a successful phase I clinical trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below